Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 41Gastrointestinal 12Thoracic 7CNS 6Head & Neck 5Dermatologic 5Tumor-Agnostic 4Sarcoma 3Endocrine 3Gynecologic 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Pheochromocytoma 2Paraganglioma 2Neoplasm Metastasis 1Carcinoid Tumor 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Axitinib × Endocrine × Clear all
NCT03839498 2026-03-02

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Columbia University

Phase 2 Active not recruiting
6 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT01967576 2021-01-06

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
14 enrolled 12 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT01435122 2018-10-02

A Study of Axitinib in Advanced Carcinoid Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
30 enrolled 10 charts
Endocrine

Carcinoid Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡